S0636: Erlotinib and Bevacizumab in Never-Smokers With Stage IIIB or Stage IV Primary Non-Small Cell Lung Cancer

DISEASE CHARACTERISTICS:

* Histologically or cytologically confirmed non-small cell lung cancer (NSCLC)

  * Adenocarcinoma

    * No component of squamous cell carcinoma present
  * Incompletely resected or unresectable disease
* Stage IIIB or IV disease as defined below:

  * Selected stage IIIB disease

    * T4 (cytologically confirmed malignant pleural effusion OR pleural tumor foci that are separate from direct pleural invasion by the primary tumor)
    * Any N
    * M0
  * Stage IV disease

    * Any T
    * Any N
    * M1 (distant metastases present)
    * Recurrent lung cancer in a separate lobe after resection or radiotherapy within the past 5 years OR multifocal lesions in \> 1 lobe considered stage IV disease
* New lesions occurring ≥ 5 years after resection may be considered a separate primary cancer and are not allowed if this is the only focus of lung cancer
* Measurable and/or nonmeasurable disease by CT scan, positron emission tomography scan, or MRI

  * Disease must be present outside a previous radiotherapy field OR a new lesion must be inside the port
  * Measurable disease must be assessed within the past 28 days
  * Nonmeasurable disease must be assessed within the past 42 days
  * Pleural effusions, ascites, and laboratory parameters are not acceptable as the only evidence of disease
* Must be a lifelong nonsmoker (\< 100 cigarettes in lifetime)
* Treated brain metastases allowed provided the patient is asymptomatic and do not require steroids

PATIENT CHARACTERISTICS:

* Zubrod performance status 0-2
* Absolute neutrophil count ≥ 1,500/mm\^3
* Platelet count ≥ 100,000/mm\^3
* Total bilirubin normal
* SGOT or SGPT ≤ 2.5 times upper limit of normal (ULN) (5 times ULN if liver metastases present)
* Alkaline phosphatase ≤ 2.5 times ULN (5 times ULN if bone metastases present)
* Creatinine ≤ 1.5 times ULN OR creatinine clearance ≥ 50 mL/min
* Urine protein:creatinine ratio ≤ 0.5 OR urine protein \< 1,000 mg by 24-hour urine collection
* Not pregnant or nursing
* Negative pregnancy test
* Fertile patients must use effective contraception
* Hypertension allowed if controlled on medication prior to study enrollment
* Must be willing to provide prior smoking history
* No immediate life-threatening complications from malignancies
* No prior major medical condition, psychological condition, or social situation that would preclude study treatment
* No hemoptysis ≥ ½ teaspoon within the past 28 days
* No clinical history of pulmonary or upper respiratory hemorrhage ≥ grade 2 within the past 6 months or grade 1 within the past 28 days
* No history of either thrombosis or hemorrhage, including hemorrhagic or thrombotic stroke, or other CNS bleeding
* No serious nonhealing wound, ulcer, or bone fracture
* No other prior malignancy except for the following:

  * Adequately treated basal cell or squamous cell skin cancer
  * Adequately treated stage I or II cancer from which the patient is currently in complete remission
  * In situ cervical cancer
  * Any other cancer from which the patient has been disease-free for 5 years

PRIOR CONCURRENT THERAPY:

* See Disease Characteristics
* At least 7 days since prior fine-needle aspiration or core biopsy
* At least 28 days since prior radiotherapy (14 days for palliative radiotherapy) and recovered
* At least 28 days since prior surgery (e.g., thoracic or other major surgeries) and recovered
* At least 28 days since prior systemic chemotherapy
* Prior biologic therapy allowed
* No prior gefitinib, erlotinib hydrochloride, bevacizumab, or other targeted therapies against the epidermal growth factor receptor or vascular endothelial growth factor axes
* Concurrent stable, therapeutic anticoagulation therapy allowed (e.g., warfarin or low molecular weight heparin), provided the patient has no history of bleeding complications on anticoagulation or an inability to establish a stable therapeutic regimen for anticoagulation
* No concurrent surgery
* No other concurrent nonprotocol treatment (including chemotherapy, hormonal therapy, biological therapy, or radiotherapy) directed at this cancer